Patrick Wen, MD
Neurology · Boston, MANPI 1053393496
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $104,384 of the $156,554 with a category attached, or 66.7%. 18 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 24.3% of the total. Reporting peaked in 2024 at $48,474 and has fallen 92.3% since, to $3,725 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $1630.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$38K
- Merck$27K
- Servier Affaires Medicales$20K
- Novocure Inc.$16K
- Bayer$14K
- E.r. Squibb & Sons, L.L.C.$10K
- plus $33K from 12 others
Across 653 payments — averaging $28,304 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Pharmaceuticals LLC$5.2M
- Servier Bioinnovation$5.1M
- Merck$4.7M
- AstraZeneca$1.5M
- Novartis$550K
- Agios Pharmaceuticals, Inc.$432K
- plus $1.1M from 11 others
What the payments were for
- Consulting fees$104,38467%
- Speaking & faculty fees$27,22217%
- Travel & lodging$22,98915%
- Food & beverage$1,9421%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 13 | $38,049 |
| Merck | 19 | $26,717 |
| Servier Affaires Medicales | 8 | $19,692 |
| Novocure Inc. | 10 | $15,800 |
| Bayer | 9 | $13,728 |
| E.r. Squibb & Sons, L.L.C. | 7 | $9,697 |
| GSK | 3 | $5,800 |
| Blue Earth Diagnostics | 3 | $5,775 |
| Boehringer Ingelheim | 1 | $5,445 |
| Novartis | 1 | $3,906 |
| Telix Pharmaceuticals | 3 | $3,064 |
| Agios Pharmaceuticals, Inc. | 3 | $2,382 |
| Novartis Pharma AG | 1 | $1,533 |
| Biogen | 2 | $1,508 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,500 |
| AstraZeneca | 9 | $974 |
| Insightec,inc | 2 | $788 |
| Servier Bioinnovation | 1 | $197 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$156,554 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.